✦
Emerging Tech · Ones to Watch
Adaptyx: Continuous Biomarker Monitoring for the Always-On Era
First published June 2026 · Pipeline coverage — not yet available for purchase
Most health testing captures a single moment. Adaptyx is building a wearable biosensor patch that captures the full movie — a continuous stream of biomarker data from interstitial fluid, powered by programmable molecular switches and AI. It's pre-commercial and FDA review hasn't begun, but the science is unusually serious. This is one to follow.
🔬
Pipeline product
Adaptyx is in active development and is not currently available for purchase. Human feasibility studies are underway. MYM will cover this product as it progresses and publish a full review when it reaches the market.
What Adaptyx is building
The Adaptyx platform is a wearable biosensor patch that uses a minimally-invasive dermal probe to interrogate biomarkers in interstitial fluid — the fluid that surrounds cells just beneath the skin. Instead of a single blood draw, it produces a continuous stream of molecular data at whatever cadence the clinical situation demands.
The core innovation is a "programmable molecular switch" platform: engineered structures that bind to specific biomarkers, changing shape when they do, and generating a unique measurable signal. Multiple switches can be printed side-by-side on the same probe, enabling simultaneous measurement of different analytes — something traditional lab assays do one test at a time. On top of that sits an AI layer that turns multiplexed streams into trends, alerts, and clinician dashboards.
The technology comes out of 17 years of Stanford-led research. Adaptyx has exclusively licensed 9 patent families and validated 12+ analytes. Human feasibility studies are currently underway.
Why continuous matters
Hormones, electrolytes, and drug levels don't sit still between blood draws. Cortisol peaks and troughs across the day. Potassium in a heart failure patient can shift dangerously within hours. A single snapshot at a clinic visit captures none of that dynamic information — which is precisely what drives missed inflection points, late interventions, and preventable hospitalizations.
Target analytes and use cases
Adaptyx has identified five initial clinical focus areas. These aren't speculative — they're the highest-impact use cases where continuous biochemical data has the clearest evidence base for improving outcomes.
Heart Failure
NT-proBNP · Potassium · Sodium · Creatinine
Chronic Kidney Disease
Potassium · Sodium · Creatinine · Urea
Hormone Dysregulation
Cortisol · DHEAS · Sex & metabolic hormones
ICU / ER / OR
Lactate · Electrolytes · Kidney function · Drugs · pH
Precision Pharmacology
Narrow therapeutic index drugs · New drugs in development
Where they are in development
Platform science established
17 years of Stanford-led R&D · 9 patent families licensed · 12+ analytes validated in the lab
Human feasibility studies — in progress
Active as of mid-2026 · Results will determine readiness for pivotal trials
Pivotal clinical trials
Not yet started · Will be required before FDA submission
FDA clearance or approval
Regulatory pathway not yet determined · De Novo or PMA likely given novelty
Commercial launch
Timeline unknown · Clinical market likely first; DTC pathway unclear
What to watch for
→Human feasibility study results. This is the first major proof point. Do the signals hold up in real bodies the way they do in the lab? Accuracy, signal stability, and skin tolerability are the key questions.
→Which analyte they lead with. Cortisol continuous monitoring for the DTC market would be a different product than an ICU electrolyte monitor. The first regulatory submission will reveal what Adaptyx sees as their fastest path to market.
→Whether they pursue DTC or clinical first. Most complex biosensors land in hospitals before homes. A clinical-first strategy is likely, but their long-term vision hints at consumer health applications — especially for hormones.
→Independent validation publications. The 17 years of Stanford research needs peer-reviewed data tied to the actual Adaptyx device. Watch for pre-prints and journal publications from feasibility trials.
Why MYM is watching this
"Continuous biomarker monitoring is the most significant structural gap in consumer health diagnostics right now. A blood draw is a photo; Adaptyx is trying to build the video. The science is deep, the team has a credible research pedigree, and the use cases are real clinical problems — not solutions in search of a problem. If the human feasibility data holds, this could become one of the most important platforms in health monitoring. We'll be following every development milestone."